| (The Editor's Pick is a new newsletter from The Hindu that provides a snapshot of the most important stories from today's edition of our newspaper, along with a note from our top editors on why we chose to give prominence to these stories.)
The Serum Institute of India has been asked by the Drug Controller of India to explain why it is still continuing with the trials involving the Oxford-AstraZeneca COVID-19 vaccine. U.K.-based AstraZeneca has put its Phase-3 vaccine trials on hold after a severe adverse reaction was reported in one of the participants. The Serum Institute's trial in India involves AstraZeneca's vaccine AZD1222, and its own COVISHIELD, which is of a similar structure. Though Serum Institute's trials in India have not shown any adverse results, as per the letter from DCI, it will have to explain AstraZeneca's adverse results and establish patient safety. With no medical cure in sight, the race for a vaccine is intense now. There is political pressure as well to expedite the tried and tested global vaccine development approval processes. In the U.S., President Trump has an Operation Warp Speed running to develop a vaccine by year-end, which matches with the U.S. election dates. Russia approved its indigenously developed vaccine even before crucial Phase-3 trials. Its vaccine is named Sputnik V, a throwback to the days of the space race when the USSR was outgunning the U.S. In India, a letter from the Director General of the ICMR pushed for India's vaccine candidate, Covaxin from BBIL, to be ready by August 15, Independence Day. The Serum Institute had made a calculated risk in investing on the testing and production of Oxford-AstraZeneca vaccine. The keen public interest in the development of the vaccine, the political pressures at play globally in vaccine development, and the Serum Institute's own risks, make this story important. | 
⇉〖OpenLoad〗 2020 Superintelligence PelÃcula Completa En LÃnea released 2020. story: La vida de Carol Peters se trastorna cuando es selecci...
Post a Comment